UBS Group AG Has $6.87 Million Position in Amphastar Pharmaceuticals, Inc. $AMPH

UBS Group AG reduced its holdings in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 17.8% during the 4th quarter, HoldingsChannel reports. The firm owned 256,624 shares of the company’s stock after selling 55,650 shares during the quarter. UBS Group AG’s holdings in Amphastar Pharmaceuticals were worth $6,872,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. FNY Investment Advisers LLC acquired a new stake in shares of Amphastar Pharmaceuticals in the third quarter valued at about $26,000. Quarry LP acquired a new stake in shares of Amphastar Pharmaceuticals in the third quarter valued at about $32,000. Farther Finance Advisors LLC grew its position in shares of Amphastar Pharmaceuticals by 46.3% in the fourth quarter. Farther Finance Advisors LLC now owns 1,381 shares of the company’s stock valued at $37,000 after purchasing an additional 437 shares during the last quarter. GAMMA Investing LLC grew its position in shares of Amphastar Pharmaceuticals by 37.8% in the fourth quarter. GAMMA Investing LLC now owns 1,685 shares of the company’s stock valued at $45,000 after purchasing an additional 462 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. grew its position in shares of Amphastar Pharmaceuticals by 24.2% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,233 shares of the company’s stock valued at $60,000 after purchasing an additional 435 shares during the last quarter. 65.09% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

AMPH has been the topic of several research analyst reports. Needham & Company LLC reaffirmed a “hold” rating on shares of Amphastar Pharmaceuticals in a research report on Friday, May 8th. Weiss Ratings cut shares of Amphastar Pharmaceuticals from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Friday, April 10th. Barclays reduced their target price on shares of Amphastar Pharmaceuticals from $30.00 to $23.00 and set an “equal weight” rating for the company in a research note on Wednesday, April 8th. Jefferies Financial Group reiterated a “hold” rating and issued a $22.00 target price (down from $30.00) on shares of Amphastar Pharmaceuticals in a research note on Tuesday, April 21st. Finally, Wells Fargo & Company reiterated an “equal weight” rating and issued a $19.00 target price (down from $30.00) on shares of Amphastar Pharmaceuticals in a research note on Thursday, May 14th. Seven investment analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Reduce” and an average price target of $24.50.

Amphastar Pharmaceuticals Stock Up 3.6%

NASDAQ AMPH opened at $17.82 on Wednesday. The company has a debt-to-equity ratio of 0.79, a quick ratio of 2.82 and a current ratio of 3.85. The firm has a 50-day simple moving average of $20.14 and a 200 day simple moving average of $24.21. Amphastar Pharmaceuticals, Inc. has a twelve month low of $16.65 and a twelve month high of $31.26. The stock has a market cap of $785.68 million, a PE ratio of 10.74, a PEG ratio of 2.79 and a beta of 0.97.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last released its earnings results on Thursday, May 7th. The company reported $0.42 earnings per share for the quarter, missing the consensus estimate of $0.70 by ($0.28). Amphastar Pharmaceuticals had a net margin of 11.00% and a return on equity of 15.12%. The company had revenue of $171.17 million during the quarter, compared to the consensus estimate of $173.46 million. On average, research analysts forecast that Amphastar Pharmaceuticals, Inc. will post 2.93 EPS for the current year.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company headquartered in Rancho Cucamonga, California. Founded in 2004, Amphastar focuses on the development, manufacturing and commercialization of injectable and inhalation products. The company’s manufacturing facilities in California produce both generic and proprietary formulations designed to address urgent and chronic medical conditions.

Amphastar’s portfolio includes a range of injectable generics such as epinephrine, naloxone and lidocaine, serving hospital, emergency medical and retail pharmacy channels.